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CHAPTER 2.1
Novel STAT1 gain-of-function variant
A Novel Heterozygous Mutation in the STAT1 SH2 Domain 
Causes Chronic Mucocutaneous Candidiasis, Atypically 
Diverse Infections, Autoimmunity and Impaired Cytokine 
Regulation
Kornvalee Meesilpavikkai1,2,5, Willem A. Dik1a, Benjamin Schrijver1a, Nicole 
M. A. Nagtzaam1a, Angelique van Rijswijk1a, Gertjan J. Driessen1,3, Peter J. 
van der Spek4, P. Martin van Hagen1,2, and Virgil A.S.H. Dalm1,2* 
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Abstract
 Chronic mucocutaneous candidiasis (CMC) is a primary immunodeficiency 
(PID) characterized by persistent or recurrent skin and mucosal surface infections 
with Candida species. Different gene mutations leading to CMC have been identified. 
These include various heterozygous gain-of-function (GOF) mutations in signal 
transducer and activator of transcription 1 (STAT1) that are not only associated 
with infections but also with autoimmune manifestations. Recently, two STAT1 
GOF mutations involving the Src homology 2 (SH2) domain have been reported 
while so far over fifty mutations have been described mainly in the coiled-coil and 
the DNA binding domains. Here we present two members of a Dutch family with a 
novel STAT1 mutation located in the SH2 domain. T lymphocytes of these patients 
revealed STAT1 hyperphosphorylation and higher expression of STAT1 target 
genes. The clinical picture of CMC in our patients could be explained by diminished 
production of interleukin (IL)-17 and IL-22, cytokines important in the protection 
against fungal infections.
Introduction
 Patient 1 (II-4) (Figure 1A-B) is a 24-year-old female who presented at age 
1 with a Streptococcus haemolyticus jaw abscess, with recurrent oral and esophageal 
Candida albicans infections from the age of 6 onwards and an episode of Staphy-
lococcus aureus pneumonia and CMV pneumonia at age of 7 years. At age 8 she 
developed hypothyroidism and there were serologic signs of celiac disease, without 
clinical relevance. Moreover, additional immunological analysis revealed presence 
of ANA in high titer (1:5120), anti-SSA, and anti-CENP-B autoantibodies. At 
the age of 20 she developed autoimmune hemolytic anemia. Over the past years, 
the clinical picture has been dominated by recurrent oral and esophageal Candida 
albicans infections for which she was repetitively treated with antifungal therapies. 
To prevent recurrence of Candida albicans infections she is currently treated with 
prophylactic antifungal therapy (fluconazole 200 mg once daily). Moreover, she 
has experienced oral and vaginal ulcers which were found negative for bacterial, 
fungal and viral microbes as determined by culture and/or PCR of oral and vaginal 
swabs and tissue biopsies from vaginal ulcers. Because of these ulcers, which were 
assumed to be autoimmune manifestations related to CMC, various immunosup-
pressive therapies have been initiated over time, including steroids, azathioprine, 
hydroxychloroquine, mycophenolate mofetil, all with little benefit. She has recently 
started treatment with adalimumab (anti-tumor necrosis factor (TNF)-α) 40 mg 
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every other week, which resulted in complete resolution of oral and vaginal ulcers 
after 3 subcutaneous injections. After three months of treatment, there is still no 
recurrence of oral and/or vaginal ulcers, whereas no increased incidence of infectious 
complications was reported while using anti-TNF-α treatment. 
 Peripheral blood total CD3+ T lymphocyte numbers (1.63×109/L [reference 
value: 0.7-2.1×109/L]), CD4+ T lymphocyte numbers (0.6×109/L [reference value: 
0.3-1.4×109/L]), CD8+ T lymphocyte numbers (0.84×109/L [reference value: 
0.2-0.9×109/L]), total CD19+ B lymphocyte numbers (0.16×109/L [reference value: 
0.1-0.4×109/L]) and CD16+ CD56+ NK cell numbers (0.1×109/L [reference value: 
0.1-0.4×109/L]) were within the normal reference ranges. Immunoglobulin levels 
were also found to be within normal limits (IgG 10.5 g/l [reference value: 7.0-16.0 
g/l], IgA 1.24 g/l [reference value: 0.76-3.91 g/l] and IgM 1.12 g/l [reference value: 
0.45-2.30 g/l]). The patient was negative for autoantibodies against IL-17A, IL-17F 
and IL-22. After immunization with a polysaccharide vaccine against Streptococcus 
pneumonia (Pneumovax), IgG antibody concentration to all 16 serotypes (1, 3, 4, 5, 
6B, 7F, 8, 9V, 14, 15B, 18C, 19A, 19F, 20, 23F, and 33F) measured increased when 
compared to pre-vaccination concentrations and for 12 serotypes the post-immuni-
zation concentrations reached values above 1 μg/ml, which is indicative of a normal 
response to polysaccharide immunization1.
 Patient 2 (I-1) (Figure 1A-B) is the 50-year-old father of patient 1, with 
a medical history including aortic valve replacement at age 29 and surgical and 
antibiotic treatment for a culture-negative, frontal-lobe brain abscess at age 33. He 
presented for the first time at our outpatient clinic at the age of 49 because of very 
severe Candida albicans infection in the oral cavity and esophagus. At that time he had 
already suffered from recurrent oral and esophageal fungal infections for years, for 
which he was treated with antifungal therapies by his general physician. Microbio-
logical analysis revealed a fluconazole-resistant Candida albicans and treatment with 
posaconazole 400 mg once daily was initiated with prompt clinical improvement. 
Subsequently, prophylactic posaconazole 200 mg once daily has been prescribed. At 
time of first analysis, also autoimmune hypothyroidism with positivity for anti-thy-
roglobulin antibodies, ANA and lupus anticoagulant were detected. Peripheral blood 
total CD3+ T lymphocyte numbers (1.06×109/L [reference value: 0.7-2.1×109/L]), 
CD4+ T lymphocyte numbers (0.5×109/L [reference value: 0.3-1.4×109/L]), 
CD8+ T lymphocyte numbers (0.52×109/L [reference value: 0.2-0.9×109/L]), total 
CD19+ B lymphocyte numbers (0.35×109/L [reference value: 0.1-0.4×109/L]) and 
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CD16+ CD56+ NK cell numbers (0.16×109/L [reference value: 0.1-0.4×109/L]) 
were within the normal reference range. Immunoglobulin levels were also found 
within normal limits (IgG 12.9 g/l [reference value: 7.0-16.0 g/l], IgA 1.65 g/l 
[reference value: 0.76-3.91 g/l] and IgM 0.8 g/l [reference value: 0.45-2.30 g/l]). 
The patient was negative for autoantibodies against IL-17A, IL-17F and IL-22. 
 
Figure 1. (A) Family pedigree of patients. Symbols in black indicate individuals with the same 
genetic defect and arrow signs indicate the patients enrolled in this study. (B) Table showing 
clinical data of all four affected individuals. (C) Sanger DNA sequencing chromatogram of mu-
tated STAT1 gene. (D) Evolutionary conservation of p.Val653 among species. (E) Three-dimen-
sional structure of phosphorylated STAT1 protein with the mutation (Val653Ile), the phosphory-
lation site (pTyr701) and the target DNA indicated.
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 Sanger sequencing from all affected individuals in the family revealed 
a novel heterozygous STAT1 mutation in exon 22 at c.1957G>A, while genetic 
testing for mutations in 276 other known genes involved in PID was negative 
(Table 1). The nucleotide base change we identified has not been reported as single 
nucleotide polymorphism (the Human Gene Mutation Database, the National 
Center of Biotechnology Information, the ExAC database, the 1000G database and 
the Ensembl database). The identified mutation results in replacement of a highly 
conserved valine at position 653 (vertebrate Phylop100 score 3.798 and SiPhy score 
19.656) (Figure 1C-D) into isoleucine (p.(Val653Ile)) within the SH2 domain of 
STAT1. The mutation is exposed on the outer surface of the molecule and within the 
vicinity of the phosphorylation site (Figure 1E). The Val653Ile mutation is predicted 
to hardly affect the overall structure of STAT1 and was predicted as ‘tolerated’ 
by the Sort Intolerant From Tolerant (SIFT) algorithm (score 0.58). However, 
Val653Ile was predicted as ‘possibly damaging’ by the Polymorphism Phenotyping 
v2 (PolyPhen-2, score 0.919), the mutation was speculated as ‘disease causing’ from 
the Mutation Taster and was scaled in Combined Annotation Dependent Depletion 
(CADD) algorithm with a score of 14.99, which suggests potential deleteriousness.
 To evaluate the immunological phenotype associated with this mutation, 
STAT1 phosphorylation was studied by flow cytometry of fresh whole blood 
samples from patient 1 and an age-gender-race-matched healthy control. After 
stimulation with interferon (IFN)-α (104 IU/ml; PeproTech, London, UK), IFN-β 
(103 IU/ml; tebu-bio, Le-Perray-en-Yvelines, France), IFN-g (105 IU/ml; R&D 
systems, Abingdon, UK) for 30 minutes or IL-6 (100 ng/ml; R&D systems) for 15 
minutes, cells were fixed and permeabilized with permeabilizing reagent (Phospho-
Epitopes Exposure kit; Beckman Coulter). All samples were stained with CD3 
(APC-conjugated anti-human CD3; BD Biosciences, California, USA) and Fluor® 
488-conjugated phospho-STAT1 Tyr701 antibodies (Cell Signaling Technology, 
Massachusetts, USA). The levels of STAT1 phosphorylation in the CD3+ T 
lymphocytes from the patient were higher than the levels observed in the healthy 
control after stimulation with IFNs (Figure 2A) or IL-6 (data not shown). To study 
the kinetics of STAT1 phosphorylation in more detail, time-course stimulation 
experiments were performed with fresh whole blood samples from patient 1 and 
patient 2 along with age-gender-race-matched healthy controls. The patients clearly 
displayed higher levels of STAT1 phosphorylation, yet the phosphorylation levels of 
both the patients and controls normalized over time (Figure 2B). 
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Figure 2. STAT1 phosphorylation evaluated by intracellular staining flow cytometry after stimula-
tion with IFN-α, IFN-β or IFN-γ. (A) Histograms showing MFI of phosphorylated STAT1 (pSTAT1) 
in CD3+ T lymphocytes (in fresh whole blood) of patient P1 and healthy control (HC1) after stimu-
lation with IFN-α, IFN-β or IFN-γ for 30 minutes. (B) Kinetics of STAT1 phosphorylation in CD3+ T 
lymphocytes (in fresh whole blood) of the two patients and two healthy controls after stimulation 
with IFN-α, IFN-β or IFN-γ. (C) Kinetics of STAT1 phosphorylation in T lymphocyte cultures from 
both patients and healthy controls. HC, healthy control; P, patient; US, unstimulated; MFI, mean 
fluorescence intensity.
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 Table 1 List of PID causing genes evaluated 
in the affected individuals
ACP5
ACTB
ADA
ADAR
AICDA
AIRE
AK2
AP3B1
APOL1
ATM
B2M
BCL10
BLM
BLNK
BTK
C1QA
C1QB
C1QC
C1R
C1S
C2
C3
C4A
C4B
C5
C6
C7
C8A
C8B
C8G
C9
C9orf142
CARD11
CARD14
CARD9
CASP10
CASP8
CCBE1
CD16
CD19
CD20
CD21
CD247
CD27
CD3D
CD3E
CD3G
CD3Z
CD40
CD40LG
CD46
CD59
CD79A
CD79B
CD81
CD8A
CEBPE
CECR1
CFB
CFD
CFH
CFHR1
CFHR2
CFHR3
CFHR4
CFHR5
CFI
CFP
CHD7
CIITA
CLPB
COH1
COLEC11
COPA
CORO1A
CR2
CR3
CSF2RA
CSF3R
CTPS1
CTSC
CXCR4
CYBA
CYBB
DCLRE1B
DCLRE1C
DKC1
DNMT3B
DOCK8
DPKC
ELANE
EPG5
FADD
FAS
FASLG
FCN3
FERMT3
FOXN1
FOXP3
FPR1
G6PC3
G6PT1
GATA2
GFI1
HAX1
ICOS
IFIH1
IFNGR1
IFNGR2
IGLL1
IKBKB
IKBKG
IKZF1
IL10
IL10RA
IL10RB
IL12B
IL12RB1
IL17F
IL17RA
IL17RC
IL1RN
IL21R
IL2RA
IL2RG
IL36RN
IL7R
INO80
IRAK4
IRF7
IRF8
ISG15
ITCH
ITGB2
ITK
JAGN1
JAK3
KINDLIN-3
KRAS
LAMTOR2
LCK
LIG4
LPIN2
LRBA
LYST
MAGT1
MALT1
MAP3K14
MASP1
MASP2
MCM4
MEFV
MRE11A
MS4A1
MSH6
MTHFD1
MVK
MYD88
NBN
NCF1
NCF2
NCF4
NFAT5
NFKB2
NFKBIA
NHEJ1
NHP2
NLRP12
NLRP3
NOD2
NOP10
NRAS
ORAI1
OX40
PARN
PGM3
PIK3CD
PIK3R1
PLCG2
PLDN
PMS2
PNP
POLE
PRF1
PRKCD
PRKDC
PSMB8
PSTPIP1
PTPRC
RAB27A
RAC2
RAG1
RAG2
RBCK1
RFX5
RFXANK
RFXAP
RHOH
RMRP
RNASEH2A
RNASEH2B
RNASEH2C
RNF168
RNF31
RORC
RPSA
RTEL1
SAMHD1
SBDS
SEMA3E
SERPING1
SH2D1A
SH3BP2
SLC29A3
SLC35C1
SLC37A4
SLC46A1
SMARCAL1
SP110
SPINK5
STAT1
STAT2
STAT3
STAT5B
STIM1
STK4
STX11
STXBP2
TAP1
TAP2
TAPBP
TAZ
TBK1
TBX1
TCF3
TCN2
TERC
TERT
THBD
TICAM1
TINF2
TLR3
TMC6
TMC8
TMEM173
TNFRSF13B
TNFRSF13C
TNFRSF1A
TNFRSF4
TNFRSF6
TNFSF12
TNFSF6
TPP1
TPP2
TRAC
TRAF3
TRAF3IP2
TREX1
TRNT1A
TTC7A
TYK2
UNC119
UNC13D
UNC93B1
UNG
USB1
VPS13B
VPS45
WAS
WIPF1
XIAP
XLF
XRCC4
XRCC5
XRCC6
ZAP70
ZBTB24
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 Because we found a higher basal level of phosphorylated STAT1 in patient 1 
(Figure 3) we established T lymphocyte cultures to reduce the confounding effects 
of exposure of both patients to different pathogens and therapies. Long-term T 
lymphocyte cultures were expanded from peripheral blood mononuclear cells (PBMC) 
of both patients and two age-gender-race matched healthy controls in RPMI-1640 
medium (Lonza, Basel, Switzerland) containing 10% heat inactivated human 
serum and antibiotics (2% penicillin and streptomycin; Cambrex BioWhittaker, 
Verviers, Belgium) in the presence of Phytohemagglutinin PHA-P (1 μg/ml; 
Sigma-Aldrich, Missouri, USA), IL-2 (25 IU/ml; Novartis, Basel, Switzerland), 
IL-15 (12.5 ng/ml; BioLegend, California, USA) and γ-irradiated (40 Gy) allogeneic 
PBMC and EBV-negative B lymphocytes. After 2 weeks of culturing, T lymphocyte 
cultures (purity > 90%) from both patients and healthy controls were analyzed 
for STAT1 phosphorylation in a manner similar to the whole blood samples. IFN 
stimulation resulted in higher generation of phosphorylated STAT1 (pSTAT1) in 
the T lymphocyte cultures from patients compared to healthy controls (Figure 2C). 
Stimulation of T lymphocyte cultures with IL-6 (100 ng/ml) yielded comparable 
results on pSTAT1 as IFN-γ (data not shown). T lymphocytes from the patients 
and healthy controls displayed similar levels of total STAT1 protein (determined by 
flow cytometry using a PE-conjugated STAT1 antibody (BD Biosciences; data not 
shown)). STAT3 phosphorylation was also evaluated after stimulation with IL-6 
(100 ng/ml) or IL-21 (200 ng/ml; Life Technologies, Massachusetts, USA) but did 
not differ between patients and healthy controls (data not shown).
 
Figure 3. Histogram showing MFI of phosphorylated STAT1 in CD3+ T lymphocytes evaluated 
by intracellular staining flow cytometry (in fresh whole blood) at basal level. HC, healthy control; 
P, patient; MFI, mean fluorescence intensity.
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 To assess the effect of the STAT1 mutation on cytokine production, PBMC 
of both patients and five race-matched healthy controls were freshly prepared and 
stimulated with heat-killed Candida albicans (HKCA: 106 cells). Supernatants were 
collected and levels of cytokines were measured by ELISA (R&D systems). Cells 
were also stimulated with phorbol 12-myristate 13-acetate (PMA) (81 nM) and 
ionomycin (I) (1.3 µM; eBioscience, California, USA) as positive control. PBMC 
from both patients produced IL-6 and IL-1β levels comparable to that of healthy 
controls, while PBMC from patient 1 did not produce IFN-g when stimulated with 
HKCA (Figure 4A). In contrast to PBMC from healthy controls, PBMC from the 
patients hardly increased IL-17A, IL-17F and IL-22 production upon stimulation 
with PMA-ionomycin or HKCA (Figure 4A). STAT1 downstream target genes were 
also measured in T lymphocyte cultures. Due to limited T lymphocyte numbers in 
these cultures, only one time-point of stimulation (24 hours) with three different 
stimuli (IFN-g (105 IU/ml), IL-6 (100 ng/ml), IL-27 (200 ng/ml; R&D systems)) 
was examined. CXCL9, CXCL10 and CD274 (PD-L1) mRNA expression levels were 
determined by real-time quantitative Taqman PCR in each sample on the basis of 6 
replicates. Strikingly high mRNA levels were observed after IL-27 activation (P < 
0.001) (Figure 4B). 
Background
 Chronic and/or recurrent fungal infections may be predominant manifes-
tations in primary immunodeficiencies, especially in inherited T lymphocyte 
defects. Various syndromes have been identified that present with recurrent fungal 
infections, for example, autosomal dominant (AD) hyper-immunoglobulin E (IgE) 
syndrome (AD-HIES), autosomal recessive (AR) autoimmune polyendocrine 
syndrome type I (APS-1), and Mendelian susceptibility to mycobacterial diseases 
(MSMD). AD-CMC is a rare and severe immunodeficiency that presents with severe 
mucocutaneous fungal infections, autoimmune phenomena, cerebral aneurysms 
and increased risk of oropharyngeal and esophageal cancer2-4. In the last decade, 
various heterozygous GOF mutations in STAT1 were found to be responsible for 
AD-CMC. So far, GOF mutations were described in the coiled-coil domain and the 
DNA binding domain of STAT1 and in the past year, the GOF mutations c.1885C>T 
(p.H629Y) and c.1973G>A (p.N658S) involving the SH2 domain were described5-7. 
Chronic and/or recurrent mucocutaneous fungal infections with predominantly 
Candida albicans are the major infectious complications in patients with STAT1 GOF 
mutations and generally arise in infancy or childhood. However, more than half of 
EMC Thesis Book.indd   87 26/8/2562 BE   14:28
88 
Chapter 2
Figure 4. (A) Dot plots depicting cytokine production in supernatant from peripheral blood 
mononuclear cells (PBMC) from both patients and healthy controls (n = 5) after stimulation of 106 
PBMC with PMA-ionomycin (PMA+I) or heat-killed C. albicans (HKCA). Every symbol indicates 
an individual. US = unstimulated. (B) T lymphocyte cultures were stimulated for 24 hours with 
IFN-γ, IL-27 or IL-6 and mRNA expression levels of CXCL9, CXCL10 and CD274 (PD-L1) were 
determined by real-time quantitative Taqman PCR. Data were normalized to the housekeeping 
gene, ABL. * p < 0.05, ** p < 0.01, *** p < 0.001 when compared with healthy controls.
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the patients encounter bacterial infections, with lower respiratory tract infections 
most frequently observed. Cutaneous viral infections are also described in about 
one third of patients6,8. In addition, many patients with GOF mutations in STAT1 
develop autoimmune manifestations. Autoimmune thyroid disease is reported in 
twenty-two percent of patients. Cerebral aneurysms and cancers are among the 
most severe complications that are found more frequently and at younger age in 
these patients when compared to the general population6,8. 
Discussion
 The mutation identified in our patients is located in the STAT1 SH2 domain 
resulting in recurrent mucocutaneous Candida albicans infections, which is one of 
the clinical hallmarks of CMC. The other two family members that carry the same 
STAT1 mutation but were not included in this study also suffered from recurrent 
mucocutaneous candidiasis (Figure 1B). In addition to fungal infections, patient 1 
showed an atypical susceptibility to a wide range of pathogens as she experienced 
Streptococcus haemolyticus jaw abscess, Staphylococcus aureus pneumonia and CMV 
pneumonia. Lower respiratory tract bacterial infections can be found in about half 
of patients with STAT1 GOF mutations. However, based on previous reports, CMV 
pneumonia was described in only one percent of patients. Patient 2 also encountered 
an intracranial abscess for which surgical and antibiotic treatments were required. 
Although the pathogenic microorganism could not be isolated, invasive deep-seated 
abscesses are uncommon for patients with STAT1 GOF mutations6. Apart from 
CMC, atypical features of infections including invasive bacterial infections were also 
described in other patients carrying a STAT1 GOF mutation in the SH2 domain5-7. 
Both patient 1 and patient 2 enrolled in this study developed a variety of autoimmune 
phenomena that were displayed in both clinical and laboratory analysis.
 In response to various kinds of infections, STAT1 receives signals from 
the cell surface receptors and is subsequently phosphorylated at Tyr701. The SH2 
domain carries the pTyr701-binding site and accordingly plays an important role 
in forming a firm cross-linkage dimerization between each STAT1 monomer. The 
dimers then accumulate in the nucleus, inducing transcription of genes9. The 
mutation here described within the SH2 domain of STAT1 results in enhancement 
of STAT1 phosphorylation both upon stimulation with IFN-α/β and IFN-γ, despite 
the suggestion that the SH2 domain may not necessarily be required for STAT1 
activation by IFN-α/β10. Moreover, this mutation may possibly affect molecule 
dimerization due to its specific location within the STAT1 molecule.
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 We performed STAT phosphorylation analysis of both patients by flow 
cytometry which revealed enhancement of STAT1 phosphorylation while total STAT1 
protein was equally measured in T lymphocytes of both patients and healthy controls. 
After stimulation with cytokines, STAT1 phosphorylation in the T lymphocytes of 
both patients reached higher levels compared to the healthy controls. In contrast to 
previous reports studying mutations in other STAT1 domains11-13, we found no clear 
prolonged STAT1 phosphorylation in the T lymphocytes from the patients. The 
difference in the mutated domain of STAT1 could possibly be the cause of different 
phosphorylation characteristics. Apart from elevated pSTAT1 induction, we also 
noticed a higher basal pSTAT1 level in peripheral blood T lymphocytes from patient 
1. Stimulation of fresh whole blood from patient 2 yielded comparable results, 
although this patient showed no elevated basal level of pSTAT1 when compared to 
healthy controls. However, after re-evaluation in established T lymphocyte cultures, 
the elevated basal pSTAT1 level previously noted in the whole blood analysis of 
patient 1 disappeared. Due to the fact that patient 2 received prophylactic antifungal 
therapy while patient 1 did not at time of analysis, recurrent exposure of patient 1 
to Candida antigens could have caused the elevated basal STAT1 phosphorylation 
we observed in her whole blood analysis. Because dysregulation of STAT3 has also 
been associated with CMC, we evaluated STAT3 phosphorylation as well, but this 
was comparable between the patients and healthy controls. 
 Th17-derived cytokines are crucial in fungal defense mechanisms14,15 and 
therefore we examined the cytokine production capacity of PBMC of both patients 
as well as healthy controls upon activation with HKCA. A remarkable impairment 
in IL-17A, IL-17F and IL-22 production was found in the patients. In order to 
further examine the consequence of this novel STAT1 SH2 domain mutation, 
STAT1 downstream target genes were assessed. T lymphocyte cultures from both 
patients and healthy controls were stimulated with IFN-γ, IL-6, and IL-27. Signifi-
cantly higher mRNA levels of STAT1 downstream target genes were found in both 
patients, especially upon IL-27 activation, including CD274 (PD-L1). Overex-
pression of PD-L1 was previously observed in naïve T lymphocytes of patients with 
STAT1 GOF mutation and cytokine-induced PD-L1 expression in T lymphocytes 
was found to hamper Th17 induction16,17. Our data suggest that disturbed Th17 
differentiation and associated cytokine production most likely underlies the clinical 
picture of CMC in the patients here described.
 Since curative treatment is still unavailable, most of the patients with STAT1 
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GOF mutations receive prolonged systemic antimicrobial medications to control 
clinical symptoms of recurrent fungal infections and other infections. Similar to 
patient 2, about forty percent of the patients who require long-term antifungal 
treatment, eventually develop therapy resistance6. Immunotherapies or immuno-
suppressive therapies are considered in some patients, although the effectiveness 
still needs to be evaluated in more detail18. Surprisingly, novel therapies, like 
JAK1/2 inhibitors showed not only the potency to suppress the enhanced STAT1 
phosphorylation in CD4+ T lymphocytes but may also improve clinical outcome 
in both immunodeficiency and autoimmunity features13,19. These drugs could be 
potential future candidates for the treatment of patients with CMC with STAT1 
GOF mutations. 
Concluding Remarks
 The novel Val653Ile mutation, located in the SH2 domain of STAT1 
found in this family does not clearly result in an impaired STAT1 dephosphory-
lation rate, as was found in patients with GOF mutations in the other domains. 
However, significantly enhanced STAT1 phosphorylation in these patients results in 
higher expression of the STAT1 target genes CXCL9, CXCL10 and CD274 (PD-L1). 
Moreover, this mutation is associated with the impairment of immune cells to 
produce IL-17A, IL-17F and IL-22. The clinical symptoms of CMC could therefore 
be explained by diminished Th17 responses that are crucial for confronting fungal 
antigens. 
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To the Editor:
 Heterozygous gain-of-function (GOF) mutations in signal transducer and 
activator of transcription 1 (STAT1) have been increasingly reported worldwide1. 
Chronic mucocutaneous candidiasis (CMC) is the hallmark of STAT1 GOF 
mutations, but bacterial infections, mainly caused by Staphylococcus aureus, viral 
infections, predominantly Herpesviridae, and autoimmune manifestations are also 
commonly present1. Enhanced STAT1 phosphorylation in patients with STAT1 GOF 
mutations is associated with overexpression of programmed death ligand 1 (PD-L1) 
and abolishes T-helper 17 (Th17) responses, which is considered to represent the 
immunological cause of CMC2-4. 
 Treatment of CMC in STAT1 GOF patients includes long-term systemic 
antifungal therapy1. Considering the underlying immunologic defect, immuno-
modulatory treatment options are also explored, although sparsely and their 
effectiveness is still indecisive5. The Janus kinase (JAK) 1/2 inhibitor, ruxolitinib 
was reported beneficial in one patient, but increased IL-17 production was not 
demonstrated in this case6. Baricitinib is a novel, orally available JAK 1/2 inhibitor 
that hampers interferon (IFN) induced JAK-STAT1 signalling in immune-mediated 
diseases and was recently approved for treatment of rheumatoid arthritis7. Based on 
its mechanisms of action it was hypothesized that baricitinib could be of benefit in 
the treatment of STAT1 GOF patients. In this report, we describe a patient treated 
with baricitinib and show its potential clinical implications for treatment of patients 
with STAT1 GOF mutation.
 The patient is a 24-year-old Dutch female diagnosed with CMC based 
on heterozygous STAT1 GOF mutation at c.1957G>A (p.(V653I)) of the Src 
homology (SH) 2 domain. She also experienced other infectious complications 
and autoimmune phenomena, as described in detail previously4. Over the years, 
main clinical problems included recurrent oral and esophageal Candida albicans 
infections. Candidiasis repetitively erupted within two weeks after termination 
of a course of antifungal therapy. Therefore, prophylactic antifungal therapy was 
required. Our patient also encountered oral and vaginal ulcers that appeared of 
non-infectious nature and were assumed to represent autoimmune manifestations 
related to STAT1 GOF mutation (Figure 1). Treatment with steroids led to rapid 
improvement of these ulcers, but steroid sparing agents including azathioprine, 
hydroxychloroquine, and mycophenolate mofetil, were only of minor benefit. Upon 
treatment with anti-tumor necrosis factor (TNF)-α, adalimumab, (in combination 
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with antifungal therapy) ulcers did not reoccur.
 
 To demonstrate an evidence-based rationale to initiate baricitinib treatment, 
we first examined effectiveness of baricitinib in vitro using fresh blood from the 
patient and one age-gender-race-matched healthy control. The concentrations of 
baricitinib used in this study were based on serum levels achieved in patients on 
oral baricitinib 2-20 mg daily8. T lymphocytes from the patient displayed higher 
STAT1 phosphorylation levels when stimulated with IFN-α, IFN-β or IFN-γ than T 
lymphocytes from healthy control. IFNs induced phosphorylated STAT1 (pSTAT1) 
levels in the patient were decreased upon addition of baricitinib (Figure 2A). STAT3 
phosphorylation, which is crucial for Th17 development9, was also measured. 
Baricitinib enhanced IL-6-induced phosphorylated STAT3 (pSTAT3) level but had 
no effect on IFN-α-induced pSTAT3 in T lymphocytes from the patient (Figure 2B). 
Baricitinib at a concentration of 20 nM significantly enhanced heat-killed Candida 
albicans (HKCA) induced IL-17A production by peripheral blood mononuclear 
cells (PBMC) from the patient. However, this was not observed for higher concen-
Figure 1. Recurrent oral ulcers in the patient. Multiple shallow ulcers with erythematous borders 
were found at upper lip, lower lip and tongue.
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trations of baricitinib (100 nM and 500 nM), suggesting an immunomodulatory 
effect within a specific dose range (Figure 2C). Baricitinib did not enhance IL-17F or 
IL-22 production (data not shown). In long-term T lymphocyte cultures, baricitinib 
significantly reduced expression of the STAT1 regulated genes CXCL9, CXCL10, and 
CD274 (PD-L1) after IL-27 stimulation (Figure 2D).
 Based on the in vitro data, baricitinib treatment (2 mg once daily) was 
initiated in the patient after adalimumab treatment had been terminated for 2 
weeks. At the start of baricitinib treatment, no active candidiasis or ulcers were 
reported. Prophylactic antifungal therapy (fluconazole 200 mg once daily) was 
initially continued. As clinical condition remained stable, dose of fluconazole was 
reduced and fully tapered after three months of baricitinib. During 6 months of 
follow-up, no oral or vaginal ulcers reoccurred. Mucocutaneous candidiasis did not 
reappear even without prophylactic antifungal therapy. No clinical or biochemical 
complications were reported.
 Blood samples collected before start of baricitinib and every 2 – 4 weeks 
afterwards, were examined for STAT1/STAT3 phosphorylation, STAT1-regulated 
gene expression and cytokine production. Before treatment, pSTAT1 in T lymphocytes 
from the patient was higher than pSTAT1 in five age-gender-race-matched healthy 
controls, as reported previously4. Baricitinib treatment reduced pSTAT1 levels, 
at every time point examined (Figure 3A). STAT3 phosphorylation also declined 
upon baricitinib treatment (Figure 3B). The remarkably high expression levels of 
STAT1-regulated genes (CXCL9 and CXCL10) from patient PBMCs before baricitinib 
treatment were strongly decreased upon treatment (Figure 3C). Patient PBMCs 
obtained during baricitinib treatment displayed higher production of IL-17A, IL-17F, 
and IL-22 upon stimulation with phorbol 12-myristate 13-acetate and ionomycin 
(PMA+I) or HKCA than PBMCs obtained before treatment. However, these levels 
were much lower than those observed in healthy controls (n=5) (Figure 3D).
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 This study provides the first evidence that baricitinib could be of value 
in the treatment of patients with STAT1 GOF mutation. We demonstrate this at 
several levels. Firstly, our patient showed remarkable clinical improvement upon 
baricitinib treatment. Systemic prophylactic antifungal therapy and immunosup-
pressive treatment could be terminated, without reoccurrence of candidiasis or 
ulcers. Secondly, baricitinib reduced STAT1 hyperphosphorylation and STAT3 
phosphorylation, and improved the capacity of PBMCs to produce IL-17A, IL-17F, 
and IL-22, cytokines crucial for antifungal immune responses. Thirdly, baricitinib 
reduced expression of the IL-27/STAT-1 regulated genes CXCL9, CXCL10, and 
CD274 in long-term T lymphocyte cultures from the patient. PBMCs obtained from 
the patient during three months of baricitinib therapy also expressed CXCL9 and 
CXCL10 at levels approaching those of healthy controls. Overexpression of PD-L1 
in naïve T lymphocytes from patients with STAT1 GOF mutation is associated with 
enhanced IL-27/STAT1 signaling and contributes to inhibition of Th17 differen-
tiation2,3. An anti-human PD-L1 inhibitory antibody was found to partially rescue 
IL-17A production in T lymphocytes from patients with STAT1 GOF mutation2. 
Therefore, reduction of PD-L1 upon baricitinib treatment could contribute to the 
partial restoration of IL-17A production. In conclusion, we show for the first-time 
therapeutic benefit of the clinically available baricitinib in a patient with GOF 
STAT1. Further studies are required to evaluat e  i t s  c l i n i c a l implications in 
other patients with STAT1 GOF mutation.
Methods
STAT phosphorylation analysis
Baricitinib (Selleck Chemicals, Houston, USA) was added to cells one hour prior 
to the stimulation. Stimulations with IFN-α (104 IU/ml; PeproTech, London, UK), 
IFN-β (103 IU/ml; tebu-bio, Le-Perray-en-Yvelines, France), IFN-γ (105 IU/ml; 
R&D systems, Abingdon, UK), or IL-6 (100 ng/ml; R&D systems) were performed 
for various durations and as previously described 4. For flow cytometry analysis, 
Figure 3. (continued) (C) Bar graph depicting mRNA expression levels of CXCL9 and CXCL10 
in patient PBMC determined by qRT-PCR. Data were normalized to the housekeeping gene 
GAPDH. (D) Patient and healthy control (n=5) PBMCs were stimulated with PMA+I or HKCA. 
IL-17A, IL-17F, and IL-22 production was measured (ELISA) in culture supernatants after five 
days of culture. US, unstimulated, PMA + I = phorbol 12-myristate 13-acetate and ionomycin, 
HKCA = heat-killed Candida albicans. All the results with error bars indicate average value with 
standard error of mean (SEM).
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cells were fixed and permeabilized with permeabilizing reagent (Phospho-Epitopes 
Exposure kit; Beckman Coulter). Cells were stained with APC-conjugated antihuman 
CD3 (BD Biosciences, CA, USA), Fluor® 488-conjugated phospho-STAT1 Tyr701 
(Cell Signaling Technology, MA, USA) and PE- conjugated phospho-STAT3 Tyr705 
(Cell Signaling Technology, MA, USA) antibodies.
Cytokine production
PBMCs were cultured in RPMI-1640 medium (Lonza, Basel, Switzerland), 
containing 10% heat inactivated fetal calf serum and penicillin and streptomycin 
(Cambrex BioWhittaker, Verviers, Belgium). Baricitinib was added to the cells for 
one hour prior to stimulation with phorbol 12-myristate 13-acetate (PMA) (81 nM) 
and ionomycin (I) (1.3 μM; eBioscience, CA, USA) or heat-killed Candida albicans 
(HKCA: 106 cells). After five days of culturing, supernatant was collected and 
analyzed for IL-17A, IL-17F, and IL-22 with enzyme-linked immunosorbent assay 
(ELISA; R&D systems).
Long-term T lymphocyte culture
Long-term T lymphocyte cultures were established as previously described 4. 
After two weeks of culturing, T lymphocyte cultures with a purity of > 90% were 
obtained. Baricitinib was added to the cells for one hour prior to stimulation with 
IL-27 (200 ng/ml; R&D systems) for 24 hours. Subsequently, cells were collected 
and analyzed for CXCL9, CXCL10, and CD274 gene expression with real-time PCR. 
Real-time PCR
Total RNA was extracted from cultured cells with GenElute Mammalian Total RNA 
Miniprep Kit (Sigma-Aldrich, MO, USA) according to manufacturer’s protocol. 
RNA was reverse transcribed into cDNA with random primers (Invitrogen, Thermo 
Fisher Scientific, Waltham, MA, USA). PCR for CXCL9, CXCL10, and CD274 was 
performed using primer probe mix (Thermo Fisher Scientific) and a 7900HT 
Fast Real-Time PCR System (Applied Biosystems). Gene expression data were 
normalized to the expression of the housekeeping gene GAPDH.
EMC Thesis Book.indd   100 26/8/2562 BE   14:28
STAT1 Variant
101 
2
Statistical analysis
Statistical analysis for cytokine production experiment was performed with one-way 
ANOVA with Bonferroni’s multiple comparison test and gene expression experiment 
with t-test. All assessment was conducted with GraphPad Prism (GraphPad 
Software; San Diego, Calif software). Statistical significance was considered when 
P < .05 in all analyses.
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To the Editor:
 Aicardi-Goutières syndrome (AGS) is a rare early-onset auto-inflammatory 
disease characterized by encephalopathy, basal ganglia calcification, chronic cerebro-
spinal fluid (CSF) lymphocytosis, and elevated type I interferon (IFN) levels in the 
CSF1,2. Typical clinical manifestations include intellectual impairment, dystonia, 
and seizures. AGS patients usually experience active disease during the neonatal or 
infancy period, after which disease activity attenuates and subsequently stabilizes1,3,4. 
Apart from neurological symptoms, some patients also develop digital vasculitis or 
necrosis of the skin (chilblain), panniculitis, glaucoma, and other clinical signs that 
are also observed in systemic lupus erythematosus (SLE), including thrombocy-
topenia, arthritis, and antinuclear antibody (ANA) positivity5,6-8. 
 AGS is classified as a monogenetic type I interferonopathy with autoinflam-
mation resulting from constitutive upregulation of type I IFN signaling5. IFN-stim-
ulated genes (ISGs) are constantly overexpressed in peripheral blood cells from 
AGS patients and measurement of type I IFN signature in these cells represents a 
useful marker for AGS disease activity9,10. At least seven distinct gene mutations 
were reported, including mutations in SAMHD11,3. Loss-of-function mutations in 
SAMHD1 lead to reduced SAMHD1 enzyme activity, which is crucial for cytosolic 
deoxynucleotide (dNTP) metabolism1,2. The defective pathway of cytosolic dNTP 
induces type I IFN production via cyclic GMP–AMP synthase (cGAS), stimulator of 
IFN genes (STING), and interferon regulatory factor 9 (IRF9)1,2. 
 Janus kinase/signal transduction and activator of transcription (JAK/STAT) 
activation is crucial in the signaling cascade of numerous cytokines involved in 
the pathogenesis of various autoimmune diseases11. Consequently, treatment with 
specific JAK inhibitors including ruxolitinib and tofacitinib in immune-mediated 
diseases has been increasingly reported12,13,14. Recently, the oral JAK 1/2 inhibitor 
baricitinib was approved for the treatment of active rheumatoid arthritis and was 
also found to be effective in the treatment of a patient with chronic mucocutaneous 
candidiasis due to a STAT1 gain-of-function mutation15,16. Therefore, baricitinib is 
of potential interest to modulate the effects of IFN (over)exposure in patients with 
a type I interferonopathy. In this report, we describe an AGS patient treated with 
baricitinib and demonstrate its potential clinical applications for treatment of type I 
interferonopathies.
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 Our currently 22-year old female Caucasian patient with a consan-
guineous family history was diagnosed with AGS at the age of 19 years based on a 
homozygous nonsense mutation in exon 4 of SAMHD1 (c.490C>T, p.(Arg164Ter)). 
The identified mutation has been described previously for AGS517 and was classified 
as a disease-causing mutation in the Human Gene Mutation Database (HGMD). 
Her medical history includes subclinical hypothyroidism, short stature, and mild 
intellectual disability. Calcifications of the basal ganglia were found on computed 
tomography scan in 2007. The most prominent clinical feature is severe chilblains 
which have been active over many years. Scaly and crusted ulcers from chilblains 
were constantly observed on both hands and feet (Figure 1). The inflammation and 
pain typically exacerbated after cold exposure. 
 
Figure 1. Clinical response of AGS patient to treatment with baricitinib. Bilateral ill-defined scaly 
and erythematous patches with some minute crusted ulcers from chilblains were found on both 
hands and feet before treatment (left). Clinical improvement during 5th month of treatment (right) 
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 Baricitinib treatment was initiated at a daily dose of 2 mg. At the start of 
baricitinib treatment, the patient experienced active chilblains on both hands and 
feet. After 6 weeks of treatment, the lesions completely resolved. Until now, after 
15 months of treatment, no recurrence of chilblains was described (Figure 1). The 
lesions also did not reappear during winter, when the disease was usually active. 
Although (re)occurrence of viral infections and other opportunistic infections has 
been reported on treatment with JAK inhibitors in autoimmune disease18, these 
were not encountered by our patient. Moreover, no other clinical or biochemical 
complications were reported.
 Peripheral blood samples were collected from this patient 4 weeks prior to 
the start of baricitinib and after 2 and 6 weeks of treatment. Expression levels of 
five ISGs (IFI44, IFI44L, IFIT3, LY6E and MX1), that represent the gene signature for 
type I IFN activity19, were measured in isolated CD14+ monocytes and compared 
to the expression level of 54 healthy controls. Prior to baricitinib treatment, 
monocytes from the patient displayed higher expression of all tested ISGs compared 
to the healthy controls (Figure 2A). Expression of all five ISGs remarkably declined 
upon baricitinib treatment (Figure 2A). This data indicates that the type I IFN 
gene signature is associated with disease activity in AGS and represents a reactive 
biomarker in the context of effective treatment.
 Furthermore, we measured total STAT1 and phosphorylated STAT1 
(pSTAT1) in peripheral blood T lymphocytes by flow cytometry16. T lymphocytes 
from the patient before and during treatment expressed higher levels of total STAT1 
(Figure 2B) than that observed in T lymphocytes from two age-gender-race matched 
healthy controls. T lymphocytes from the patient before and during baricitinib 
displayed baseline levels of pSTAT1 comparable to that of the healthy controls 
(Figure 2C-D). However, T lymphocytes obtained from the patient before initiation 
of baricitinib treatment displayed far higher levels of pSTAT1 upon IFN-α stimulation 
than T lymphocytes from the healthy controls (Figure 2C-D). T lymphocytes from 
the patient that were obtained during the period of baricitinib treatment displayed a 
strong reduction in pSTAT1 upon IFN-α stimulation in comparison to that observed 
in the T lymphocytes obtained before baricitinib treatment (Figure 2C-D).
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Figure 2. Immunological responses of peripheral blood cells obtained from the patient before 
and during baricitinib treatment. Blood samples were collected before baricitinib was started and 
after 2 weeks and 6 weeks of treatment. 
EMC Thesis Book.indd   147 26/8/2562 BE   14:28
148 
Chapter 4
 
 This study demonstrates that baricitinib could be beneficial in the treatment 
of patients with AGS. This is supported by several observations. First, clinical 
improvement of the patient was found, as the chilblain lesions were completely 
healed after 6 weeks of treatment, without reoccurrence for over 15 months. 
Secondly, the high expression level of ISGs in monocytes from the patient declined 
during the treatment with baricitinib. Thirdly, despite the high total STAT1 level in 
the patients T lymphocytes, baricitinib treatment prevented STAT1 hyperphosphor-
ylation in these cells when stimulated with IFN-a.
 In summary, we present for the first time that baricitinib is a novel drug 
for the treatment of chilblains in AGS patients with a SAMHD1 mutation and 
consequent upregulation of type I IFN activity. The immunological effects of 
JAK-inhibitors depend on their selectivity and inhibitory capacity for the several 
JAK subtypes. Baricitinib displays a stronger inhibitory effect on cytokine induced 
STAT phosphorylation than ruxolitinib which was previously reported successful 
in the treatment of STING-associated type I Interferonopathy13,20. Therefore, more 
in-depth research is warranted to evaluate clinical response to baricitinib treatment 
for type I interferonopathies.
Acknowledgement
We are grateful to Prof Yanick Crow of Manchester Center for Genomic Medicine, 
Saint Mary’s Hospital, Manchester for sharing his idea that JAK inhibitor might 
work for the patient’s chilblains. 
Figure 2. (continued) (A) Box & Whisker plot (left) depicting mRNA expression levels of the 
IFN-stimulated genes (ISGs) IFI44, IFI44L, IFIT3, LY6E and MX1 in monocytes from healthy 
controls (n=54). Line graph (right) depicting mRNA expression levels of the ISGs in monocytes 
from the patient before and during the treatment. The expression levels were determined by 
qRT-PCR and the data were normalized to the housekeeping gene ABL. (B) Bar graph showing 
total STAT1 levels in T lymphocytes from the patient before and during treatment as well as in 
healthy controls. (C) Histograms showing STAT1 phosphorylation in T lymphocytes upon type I 
IFN induction. (D) Bar graphs depicting kinetics of STAT1 phosphorylation in T lymphocytes upon 
stimulation with IFN-α for the indicated time periods. MFI = mean fluorescence intensity, wks 
= weeks, BRN = baricitinib, mins = minutes, US = unstimulated. All the results with error bars 
indicate average value with standard error of mean (SEM)
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PATHOPHYSIOLOGY OF GENETIC VARIANTS IN STAT1 AND STAT3 
ASSOCIATED WITH IMMUNE DYSREGULATION IN PRIMARY 
IMMUNODEFICIENCY DISORDERS
Pathophysiology of STAT1 GOF variants
JAK/STAT signaling pathways are involved in several immunological and 
non-immunological responses. Both germline loss-of-function (LOF) and gain-of-
function (GOF) variants in STAT1 have been reported, and these mutations are 
closely related to primary immunodeficiency disorders (PIDs). While LOF variants 
in STAT1 predominantly result in immunodeficiency with increased risk for viral 
and/or mycobacterial infections, GOF variants in STAT1 lead to a clinical phenotype 
involving both immunodeficiency and autoimmunity1. Patients with STAT1 GOF 
variants are also at increased risk to develop vascular aneurysms and cancer when 
compared to the general population1. GOF variants in STAT1 are highly associated 
with enhancement of STAT1 phosphorylation. The increased phosphorylation 
pattern is determined by the STAT1 domain containing the particular variant. 
Activating variants in the coiled-coil domain (CCD) and DNA binding domain 
(DBD) of the STAT1 protein lead to increased and prolonged STAT1 phosphory-
lation. Variants located in SH2 domain, as also shown by the studies in Chapter 2.1, 
lead to increased STAT1 phosphorylation, without prolonged phosphorylation2-5. 
Moreover, GOF variants in STAT1 may also result in diminished Th17 responses in 
terms of impaired IL-17A, IL-17F, and IL-22 production and/or reduction of Th17 
lymphocyte numbers3,4,6. The disturbed Th17 function is proposed to be the major 
cause of CMC in patients with GOF variants in STAT1. The study presented in 
Chapter 2.1 also detected higher expression of STAT1-targeted genes, including 
CD274 (PD-L1) in T lymphocyte cultures carrying STAT1 GOF variant. Increased 
expression of PD-L1 was found in T lymphocytes of the patients with STAT1 
GOF variants and is associated with impairment of Th17 lineage development7,8. 
Although STAT3 is a crucial transcription factor for Th17 development, STAT3 
phosphorylation is usually unaffected in cells with the STAT1 GOF variants6. 
The pathophysiology of autoimmunity in these patients still needs to be 
explored. Notably, while CMC is also reported in the patients with LOF inborn errors 
of IL-17A/F immunity and in patients with AD-HIES, autoimmune phenotypes 
are not common in these patients. Various phenomena of immune dysregulation 
in patients with STAT1 GOF variants resemble patients with IPEX syndrome or 
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APECED. However, GOF variants in STAT1 do not disturb either IL-2-mediated 
STAT5 phosphorylation, FOXP3 expression, or (regulatory T lymphocyte) Treg 
development, while these immunological phenotypes are described in IPEX 
syndrome9. Patients with LOF variants in AIRE also display clinical overlap with 
STAT1 GOF patients including CMC, autoimmune thyroiditis, alopecia, and type 
1 diabetes. Yet, a recent study reported that STAT1 expression in monocytes from 
APECED patients was lower than that of healthy controls which is in the opposite 
direction with STAT1 activating variants10. Immune dysregulation in STAT1 GOF 
variants might be due to an increased STAT1-mediated IFN-α/β signaling which is 
also the case in patients with interferonopathies.
Patients with STAT1 GOF variants have a higher risk of developing 
aneurysms and vasculitis. Most of the vascular diseases in these patients occur in the 
central nervous system1,11. A direct role of STAT1 in aneurysm formation is not well 
established yet. Studies of the atherosclerosis process revealed that STAT1 mediates 
stimulation of aortic endothelial cell growth by the induction of vascular endothelial 
growth factor (VEGF) and angiotensin II12. Signaling of STAT1 through activation 
of TLR4 also results in expression of several pro-inflammatory and pro-atherogenic 
mediators, including CXCL10 and CCL513-15. These evidences unveil the contribution 
of STAT1 in vascular remodeling and might explain vasculitis as well as aneurysm 
formation in STAT1 activating mutations. On the other hand, a study also reported 
inhibition of IFN-γ-induced STAT1 signaling on angiogenesis through suppression 
of VEGF activity16. Therefore it can be speculated that vasculitis (with or without 
formation of aneurysms) in the patients with STAT1 GOF mutation is caused by 
type I IFN-mediated STAT1 signaling since the incidence of vascular disease seems 
to be more frequently occurring in patients with autoimmune phenotypes, partic-
ularly type I diabetes1 
 Patients with STAT1 GOF variants have an increased risk of developing 
cancer, particularly squamous cell carcinoma of the skin, oral cavity, larynx, and 
esophagus. In several types of cancer, STAT1 is known as inducer of anti-proliferative 
and pro-apoptotic genes that inhibit tumor growth17. STAT1 also generates cancer 
promoter effects in some specific circumstances. In general, the burden of inflam-
mation in inflammatory diseases is associated with development of malignancies. 
In STAT1 GOF mutations, the development of carcinoma is related to candidiasis18. 
Candida infection is known to increase the risk of tumor progression19. Although C. 
albicans is a commensal yeast of the human body, during infection, C. albicans produces 
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carcinogenic compounds including nitrosamine and acetaldehyde20. Nitrosamine is 
able to induce cellular dysplastic changes and provoke malignant tumors in various 
tissues20,21. Acetaldehyde is also related to formation of carcinogenic metabolites 
that may interfere with DNA replication and DNA repair machinery20,22. 
Pathophysiology of STAT3 GOF variants
In several studies, the function of STAT3 has been unveiled as promotor of 
cell survival and development of autoimmune diseases. In line with STAT1 variants, 
LOF variants in STAT3 result in AD-HIES with a clinical picture dominated by 
an increased risk of bacterial infections and CMC without a distinct autoimmune 
phenotype23. GOF variants in STAT3 lead to immune dysregulation disorders including 
immunodeficiency and autoimmunity24. To better understand the pathophysiology 
of each clinical symptom of patients with STAT3 GOF variants, additional in-depth 
studies and reported case series are required as the clinical phenotype of the disease 
is highly diverse. Patients with STAT3 GOF variants are susceptible to virtually all 
micro-organisms, with variable degrees of severity. Immunodeficiency in patients 
with STAT3 activating variants varies from hypogammaglobulinemia to aberrancy 
of total immune cell numbers and/or immune cell functions25-27. 
STAT3 plays an important role in the induction of inflammatory responses, 
and as expected, GOF variants in STAT3 result in multiple early onset autoimmune 
features24. However, the mechanism of autoimmunity is not always straightforward 
as the immunological phenotypes in these patients are diverse. Increase in Th17 
and/or reduction of Treg responses are mostly observed25,26. Yet, a number of 
patients experience autoimmune phenomena with normal Th17 and/or normal 
Treg responses26,27. Additionally, as STAT3 promotes cell proliferation, somatic 
GOF variants in STAT3 are also associated with T cell and NK cell large granular 
lymphocyte leukemia28,29. STAT3 may thus act as a malignancy driving transcription 
factor. Therefore, patients with germline STAT3 GOF variants may be also at risk 
for cancer. However, so far, only few patients with germline STAT3 activating 
variants have been described with large granular lymphocytic leukemia or Hodgkin 
lymphoma. Since most of the reported patients with these genetic variants are 
young, the risk of development of malignancy could increase over time and the 
treating physicians should be aware of these possible complications. 
Chapter 3 of this thesis describes two patients with a novel Y360C 
STAT3 GOF variant who developed severe pulmonary hypertension. Pulmonary 
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hypertension can develop as a consequence of pulmonary artery hypertension (PAH) 
or as a complication (secondary pulmonary hypertension), of other conditions, 
for example interstitial lung disease and cardiac conditions30,31. In our patients 
with STAT3 GOF variants, pulmonary hypertension could be a complication of 
interstitial lung disease. However, several studies also described a role for STAT3 in 
development of PAH. Therefore, it is also possible that activating variants in STAT3 
itself directly results in PAH and pulmonary hypertension. STAT3 participates in 
the pathophysiology of PAH by initiating and promoting vascular smooth muscle 
cell (VSMC) proliferation and reducing of apoptosis of these cells32,33. Subsequent 
overgrowth of these endothelial cells generates a ‘low-flow-high-resistance’ system 
from vascular constriction, elevation of pulmonary vascular resistance, and elevation 
of pulmonary pressure32,33. Binding of STAT3 to the endothelial nitric oxide synthase 
(eNOS) promoter diminishes the promotor activity and leads to reduction of eNOS 
protein level. Depletion of eNOS protein results in insufficiency of nitric oxide which 
is an endothelium-derived vasorelaxant compound as well as an inhibitor of SMC 
growth33,34. Additionally, STAT3 activation upregulates nuclear factor of activated 
T cells (NFAT) and provirus integration site for Moloney murine leukemia virus 
(Pim1)32,33. Overexpression of these two transcription factors increases VSMCs 
proliferation32. Interestingly, pulmonary artery endothelial cells from patients with 
idiopathic PAH also expressed higher level of phosphorylated STAT3 than that of 
healthy controls33,35. Endothelial cells from patients with idiopathic PAH showed 
greater response to growth factors (e.g. VEGF, basic fibroblast growth factor [bFGF], 
human epidermal growth factor [hEGF], and IGF-I) as displayed by excessive prolif-
eration rates, migration rates, and survival rate. This suggests that the IL-6/JAK/
STAT3 pathway might be a target for therapy in PAH. Indeed, the pathological 
effects were strongly reduced by a JAK2/STAT3 inhibitor, AG49035. 
The effect of STAT3 on vascular disease could also be related to the retinal 
neovascularization in our patients with the L387R STAT3 activating variant. STAT3 is 
also expressed in retinal pigmented epithelium (RPE) and is recognized as regulator 
of RPE survival, inflammation, cytokine production, and visual cycle maintenance36. 
Therefore, aberrancy in the STAT3 signaling pathway could contribute to both 
retinal vascular disease and macular edema which resulting in degeneration of the 
retina.
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INTERACTIONS BETWEEN STATS IN THE PATHOPHYSIOLOGY OF 
PIDS WITH IMMUNE DYSREGULATION
Genes of the STAT family are proposed to originate evolutionary from 
only a single STAT gene that has undergone genome duplications into seven STAT 
members in humans37. Perhaps because of this proposition, all STATs can bind to the 
same palindromic DNA motif, GAS, yet with different affinity. In the equilibrium 
state of STATs, each STAT and STAT complex binds to its preferred GAS sites. 
However, reduction in number or function of one STAT protein allows other STATs 
to compensate for its GAS binding and function. Likewise, increase in number or 
function of one STAT also competes with other STAT family members GAS bindings 
and functions38. These phenomena could explain why the patients with STAT1 GOF 
variants experience clinical symptoms that overlap with patients carrying STAT3 LOF 
variants and the patients with STAT3 GOF variants experience clinical symptoms 
that overlap with the patients carrying STAT5B LOF variants. Functional discrepancy 
between STAT homodimerizations and heterodimerizations might also explain the 
shared clinical phenotypes. As an example, the STAT1:STAT3 heterodimer might 
not bind to IL-17 encoding loci as effective as a STAT3 homodimer18. The complexity 
in pathophysiology of STAT mutations therefore likely results from similarity of the 
STATs protein structure while each STAT exerts diverse effects including opposite 
functions in biological relevant processes. 
STAT1 GOF and STAT3 LOF variants
Patients with STAT1 GOF and STAT3 LOF variants are highly vulnerable 
to candidiasis. Susceptibility to candida infections in AD-HIES patients is well-de-
scribed from reduction of STAT3-mediated Th17 response. The pathogenesis of the 
increased risk of candida infections in AD-HIES could be the same for patients 
with STAT1 GOF variants as both of these groups of patients display diminished 
Th17 counts and/or function and both experience infections mainly from the same 
organisms. IL-17 also plays an important role in the protection against bacterial, 
viral, and parasitic infections39. Therefore, apart from fungi, infections with other 
pathogens are also frequently observed in these patients. Lymphocytes from both 
of the patients with STAT1 GOF and STAT3 LOF variants displayed increased 
cytokine-induced STAT1 phosphorylation40. Additionally, STAT1-dependent PD-L1 
upregulation is highly elevated in both STAT1 GOF and STAT3 LOF lymphocytes 
and is associated with a significant reduction of SOCS3 expression8,40. STAT1- 
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dependent-upregulation of PD-L1 is associated with impairment of Th17 response8,40. 
In several cell types, an opposing role between STAT1 and STAT3 was reported 
and reduction of STAT3-dependent gene transcription is found in cells carrying 
STAT1 GOF variant40,41. Additionally, formation of STAT1:STAT3 heterodimers 
was suggested to contribute to the shared clinical phenotypes between patients 
with either STAT1 GOF or STAT3 LOF variants. STAT1:STAT3 heterodimers are 
considered to be less transcriptionally active than STAT1:STAT1 and STAT3:STAT3 
homodimers18. Therefore, in the case of STAT1 GOF variants, ligand activation leads 
to relatively high STAT1 homodimer and STAT1:STAT3 heterodimer formations, 
while STAT3 homodimer are formed at relatively low level. This situation yields 
the same as for STAT3 LOF variant in which STAT3 homodimer and STAT1:STAT3 
heterodimer formation are comparatively lower than STAT1 homodimer formation. 
Another remarkable evidence for the opposing roles between STAT1 and STAT3 is 
shown in cells carrying STAT3 GOF variant. Impairment of STAT1 phosphorylation 
was also detected in many cases with STAT3 GOF variants. Enhancement of SOCS3 
expression in cells with STAT3 GOF variant is proposed to be a feedback mechanism 
underlying the reduction of STAT1 phosphorylation in these cells26. Decreased 
phosphorylation of STAT1 in the patients with STAT3 GOF variants potentially 
relates to susceptibility to viral and/or mycobacterial infections in these patients as 
is also described in the patients with STAT1 LOF variants. 
Vascular abnormalities are also reported in patients with STAT1 GOF 
variants and HIES. Aneurysms are frequently observed vascular complications 
in both conditions. Tortuosity and dilatation of arteries are also noted in HIES42. 
Although HIES is also caused by mutations in other genes apart from STAT3 (e.g., 
DOCK8, PGM3, CARD11, TYK2), vascular abnormalities are mainly detected in 
the patients carrying AD STAT3 LOF mutation42,43. This suggests that vascular 
abnormalities could be related to decreased function of STAT3. The pathology of 
vascular anomalies in AD-HIES are hypotrophic arterial walls, elevated circumfer-
ential stress, and susceptibility to arterial dilation44. One research group suggested 
the relation of vascular abnormalities to a connective tissue defect as characterized 
in the inherited Ehlers-Danlos vascular-type syndrome, since the patients with 
AD-HIES also display joint hyperextensibility44. More data of thorough arterial 
vasculature and hemodynamic study in patients with STAT1 GOF mutations are still 
required to find the correlation between vascular abnormality in STAT1 GOF and 
STAT3 LOF variants. Several studies suggested that aneurysms reported in STAT1 
GOF variants are the consequences of inflammation of the arterial wall. However, 
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for STAT3 LOF variants, the levels of systemic inflammatory biomarkers do not 
correspond with the vascular abnormalities. Autoimmune phenotype is also not 
common in STAT3-LOF-related AD-HIES44. Vascular aneurysms in STAT3 LOF 
variants are therefore not supposed to be the effect of inflammation. However, in 
case of ruptured aneurysm, murine experiments demonstrated increase in severity 
including rupture of aneurysm after inhibition of IL-6-mediated STAT3 signaling or 
IL-17A signaling pathway44. Therefore, susceptibility to aneurysm rupture in both 
groups of patients with STAT1 GOF and STAT3 LOF variants is suggested to be the 
result of an insufficient Th17 response.
STAT3 GOF and STAT5B LOF mutations
Postnatal growth failure is one of the major phenotypes in STAT3 GOF 
variants and low levels of IGF-I were measured in most of the patients tested24. 
Therefore, growth defects in these patients are supposed to result from disruption 
of the GH/IGF-I axis. Interestingly, this phenotype is also displayed in patients with 
STAT5B LOF variants, since functional impairment of STAT5B is associated with 
partial GH insensitivity45. Growth delay in STAT3 GOF patients might be related 
to disrupted function of the GH/STAT5B pathway. In many cell types, STAT3 and 
STAT5B have different and opposing effects on gene expression45,46. There are 
four possible explanations for the opposing effects of STAT3 and STAT5B. Firstly, 
GH activates STAT1, STAT3, STAT5A, and STAT5B via JAK2. The activation of 
STAT5s upon GH regulates IGF-1, while activation of STAT1 and STAT3 results in 
STAT1:STAT3 heterodimerization and transcription of the proto-oncogene FOS46. 
Therefore, enhancement of STAT3 activation might lead to an increased formation 
of STAT1:STAT3 heterodimers which deviates GH signaling from activation of 
STAT5 as usual. In line with this, some experiments demonstrated reduction of 
STAT5B phosphorylation in cells with STAT3 activating variants25,45. In NK cells of 
the patients with STAT1 GOF variants, decreased STAT5 phosphorylation was also 
observed in one study which was restored after treating the cells with ruxolitinib47. 
Secondly, the functional reduction of STAT5B could be the effect of elevated 
expression of STAT3-regulated SOCS3 which negatively mediates JAK/STAT 
pathway signaling. However, increased SOCS3 expression was not always observed, 
for instance, normal SOCS3 expression was detected in STAT3 GOF mutation cases 
with short stature48. Thirdly, competition of STAT3 and STAT5B in binding at the 
same genetic loci is reported for the locus encoding IL-1749. This might suggest 
competitiveness between STAT3 and STAT5B regulating transcription of growth-
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related genes as well. Lastly, the opposing function of STAT1 and STAT3 is also 
shown in STAT1 GOF variant with reduction of the Th17 response as discussed 
above. The formation of STAT3:STAT5b heterodimer is also described. Perhaps an 
opposing role between STAT3 and STAT5 may occurred from nonfunctional STAT3/
STAT5B heterodimer in the same manner as with STAT1/STAT3 heterodimer45.
Both patients with STAT3 GOF and STAT5B LOF variants display immune 
dysregulation disorders. The shared clinical phenotypes include immunodeficiency, 
type I diabetes, autoimmune cytopenia, eczema, enteropathy, and autoimmune 
thyroiditis. Most of the patients with STAT3 GOF and STAT5B LOF variants show 
diminished numbers and/or function of Tregs in combination with reduced FOXP3 
expression. Notably, autoimmune phenotypes in these patients are also similar to 
patients with IPEX syndrome. Dysfunction of Tregs is therefore suggested to be 
a cause of immune dysregulation in STAT3 GOF and STAT5B LOF variants as it 
was also documented as a cause of immune dysregulation in the IPEX syndrome50. 
Autoimmune symptoms in patients with STAT3 GOF variants are usually broader 
and more severe than in STAT5B LOF variants. This might be explained by an 
increased Th17 response reported in some patients with STAT3 GOF variants. 
However, data of Th17 numbers and function in STAT5B LOF patients is required 
to link this correlation. Interestingly, STAT3 and STAT5 bind the same DNA motif 
of the IL7A–IL17F locus in a competitive manner49. Binding of STAT3 on IL17 locus 
promotes Th17 development while binding of STAT5 reverses the action. Therefore, 
fate determination of Th17 represents the balance between engagement of STAT3 
and STAT5 to the sites along the IL7A–IL17F locus49. Apart from the IL17 locus, 
STAT3 and STAT5 interact in cancer development by engaging on the same BCL6 
locus. In breast cancer cells, STAT3 increases the expression of BCL6 while STAT5 
reverses this action of STAT3 by displacing STAT3 from the shared binding site51. 
More than one-third of the patients with STAT3 GOF variants develop 
interstitial lung disease (ILD)24. Lung fibrosis is one of the complications of ILD 
and is initiated by alveolar epithelial cell injury52. Injury of alveolar epithelial 
cells generates a profibrotic environment and promotes formation of fibroblastic 
foci containing activated and proliferating (myo)fibroblasts. Accumulating (myo)
fibroblasts deposit large amounts of extracellular matrix thereby destroying the 
normal pulmonary architecture53. Of note, primary idiopathic pulmonary fibrosis is 
also one of the main concerns in patients with STAT5B LOF variants. Activation of 
STAT3 by TGF-β and IL-6 are the suggested mechanisms underlying development of 
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lung fibrosis52. Increased STAT3 phosphorylation is detected in lung fibroblasts and 
alveolar type II epithelial cells from patients with idiopathic pulmonary fibrosis52,54. 
However, the relation between STAT5 and lung fibrosis is still unexplained. 
Interestingly, over 80% of the patients with HIES display abnormal 
facial appearances55. Hemihypertrophy, prominent forehead, deep-set eyes, mild 
prognathism, broad nasal bridge, and wide and fleshy nasal tip were noted56. Skin 
changes with rough and prominent pores are also observed. Some of these features 
are similar to acromegaly which is a disorder that results from excessive levels of 
GH and IGF-1. These observations are also suggestive of the opposite function of 
STAT3 and STAT5 on the GH axis. 
 Various cases of germline STAT1, STAT3, and STAT5B variants are reported. 
Both, LOF and GOF variants identified in these genes provide precious information 
for the study of STATs biology. Comparison of the clinical phenotypes between 
STAT1 GOF and STAT3 LOF variants as well as between STAT3 GOF and STAT5B 
LOF variants illustrate the reciprocal function of STATs. Having more or less of 
any single STAT does not result in dysfunction of only one STAT but may disturb 
the equilibrium of the multi-STAT system. Keeping the balance is therefore 
indispensable for the healthy state of STATs.
JAK/STAT PATHWAYS AS TARGETS FOR THERAPY
So far, several immune dysregulations have been reported as a consequence 
of an aberration in STAT expression and/or function. Activation of certain STATs 
also participates in the development of malignancy. Therefore, it is indisputable to 
propose the JAK/STAT signaling pathway as one of the therapeutic targets in several 
diseases. Discovery of JAK inhibitors (JAKinibs) broadens the treatment options 
for several diseases, including hematologic cancers and immune-related inflam-
matory diseases. In this thesis, a JAKinib is proposed as a personalized medicine or 
precision medicine for patients with STAT GOF variants and the interferonopathy; 
Aicardi-Goutières syndrome (AGS). 
There is no practical curative treatment for STAT1 GOF variants. The only 
curative treatment identified is allogeneic hematopoietic stem cell transplantation 
(HSCT). However, the survival rate is less than fifty percent57. Majority of patients 
with STAT1 GOF variants suffer from CMC, therefore prophylaxis antifungal therapy 
is the first line of treatment in almost every case1. Long-term use of antifungal 
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medication results in drug resistance which is found in almost half of the patients 
and thus second- or third-line of treatments are required1. In the STAT1 GOF variant 
individuals who develop autoimmunity, immunosuppressive treatment is usually 
initiated. Treatment with infusion of either GM-CSF, G-CSF, or IFN-α are of minor 
benefit1. 
Administration of a JAKinib impedes activation of JAK molecules which 
occurs upstream of STAT activation58. This thesis reports a family with an inherited 
STAT1 GOF variant in the SH2 domain (Chapter 2.1). Enhancement of STAT1 
phosphorylation was identified as the consequence of the variant in STAT1 and 
responsible for the clinical phenotype including both severe immunodeficiency and 
autoimmunity. Preceding studies reported the successful treatment of patients with 
STAT1 GOF variants with the JAK1/2 inhibitor, ruxolitinib59-61. However, for the 
study conducted in this thesis (Chapter 2.2) baricitinib was selected based on its 
superior selectivity for JAK1/2 and its positive effects found in the clinical trials in 
rheumatoid arthritis and systemic lupus erythematosus62-65. The patient described 
in this thesis that was treated with baricitinib suffered from immunodeficiency, 
dominated by an increased risk of fungal infections, and a systemic lupus erythema-
tosus-like autoimmune phenotype. Baricitinib was tested in the patient cells in vitro 
to prove for the therapeutic benefit and was evaluated for dose-response before the 
administration in the patient. Interestingly, administration of baricitinib resulted in 
reduction of STAT1 hyperphosphorylation and also phosphorylation of STAT3, yet 
in a lesser extent. Although STAT3 phosphorylation was impeded in some degree 
by baricitinib, the overall outcome led to the restoration of IL-17 immunity and 
improvement of antifungal immune response. During baricitinib treatment, the 
patient experienced remarkable improvement. CMC did not reappear, even without 
prophylactic antifungal therapy. Oral and vaginal ulcers also did not reoccur. These 
results demonstrated the therapeutic benefit of baricitinib in this patient with 
STAT1 GOF variant and also supports the idea that the functional balance between 
STATs is necessary for a healthy immune system. 
In Chapter 4 the treatment of a patient with AGS with baricitinib is 
demonstrated. Up-regulation of type I IFN signaling was described as a major 
pathophysiology of AGS and results in autoinflammation66. A previous study 
reported a benefit of ruxolitinib in patients with interferonopathy67. One female 
patient who had persistent severe chilblain lupus was included in the study described 
in chapter 4. The PBMCs of this patient displayed enhanced STAT1 phosphorylation 
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upon IFN-α stimulation. Treatment with baricitinib resulted in reduction of STAT1 
hyperphosphorylation upon IFN-α activation as well as reduction of IFN-stim-
ulated signature genes which was associated with remarkable clinical improvement. 
During the treatment, IFN-activated STAT1 phosphorylation was decreased to a 
level that was much lower than the level of healthy controls. Therefore, the treating 
physician should be aware of the vulnerability to viral or mycobacterial infections as 
an adverse reaction upon baricitinib administration. However, up to now (2 years), 
there are no signs of unusual infections or reoccurrence of chilblains.
The patients with a Y360C STAT3 GOF variant that are described in this 
thesis (Chapter 3) were also treated with a JAK inhibitor. Two patients were treated 
with tofacitinib which is categorized as pan-JAK inhibitor. During tofacitinib 
administration, one of the patients was tested for serum STAT3-related cytokines, 
IL-6, IL-17A, and IL-17F. High pre-treatment levels of all measured cytokines were 
decreased during tofacitinib administration (Figure 1A-C). In vitro IL-6 production 
from PBMCs was increased upon PMA/ionomycin stimulation when compared 
to the level before the treatment. However, this IL-6 production level decreased 
again at the last time point of measurement (Figure 1D). Despite extensive drug 
interventions including tofacitinib, the clinical picture of pulmonary hypertension 
in one patient did not improve and led to death. Nevertheless, the other patient was 
treated with diuretics in combination with tofacitinib (serum cytokine and in vitro 
IL-6 measurements were not performed in this patient). Her clinical condition of 
pulmonary hypertension improved significantly and during tofacitinib treatment 
no progression of PAH was observed. This patient experienced a significant 
subjective overall clinical improvement upon tofacitinib treatment. Treatment 
failure in the patients with STAT3 GOF variants treated with a JAKinib was 
previously reported with ruxolitinib60. The ineffectiveness of the treatment 
in reversing clinical symptoms was suggested to be due to late-stage of the 
disease when ruxolitinib was started60. This could also explain the treatment 
failure in one of our patient cases. Therefore, treatment with a JAK inhibitor 
may be more successful when the it is initiated in early stage of the disease. Yet, 
studies that determine the “window of opportunity” are required. 
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Based on clinical and immunological results, the treatment with a JAKinib 
in our cases, suggests a step forward in the direction of personalized medicine. In 
the diseases caused by hyperactivation of STATs, JAKinibs could precisely inhibit 
the targeted pathway which is expected to be better than unspecific immunosup-
pressive treatment or antimicrobial therapy. However, the challenge of inhibiting  the 
STAT pathway in the treatment of immune-mediated diseases is that the dosage of 
JAKinib needs to be customized to the appropriated level, while in the treatment of 
cancer, a complete inhibition of the “target STAT” might necessary. Optimal dosage 
of JAKinibs treatment might also inhibit the other associated STAT pathways yet 
could lead to effective treatment from restoration of STATs equilibrium.
Discovery of highly specific STAT inhibitors may provide a more precise 
medication than JAKinibs for targeting the STAT pathway. However, inhibiting 
STAT is more difficult than inhibiting JAK activity due to similarity between each 
STAT structure. Additionally, inhibition of one specific STAT might generate a 
STAT LOF variant-like situation to the cells which may result in complications from 
imbalance of other STATs. Several compounds targeting SH2 domain or DBD of 
STATs have been developed but had unacceptable adverse reactions and bioavail-
ability is also the major issue63. In the near future, restoring equilibrium of STATs 
might be approached by gene therapy especially for the diseases with a monogenetic 
mutation. CRISPR-Cas gene editing may be a promising future therapeutic approach 
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Figure 1. The effect of tofacitinib on cytokine production in the patient carrying STAT3 
p.Y360C GOF variant. (A-C) Serum level of IL-6, IL-17A, and IL-17F before and during
tofacitinib administration. (D) In vitro IL-6 production by PBMCs stimulated with PMA/
Ionomycin. Data with error bar are shown as mean ± SEM.
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to recover the hematopoiesis. Several studies have demonstrated the possibility 
of using CRISPR-Cas systems in the human primary hematopoietic stem and 
progenitor cells for the treatment of hematological diseases including β-thalassemia 
and sickle cell disease68. Developing this technique for other monogenetic diseases 
could provide an effective, precise, and curative treatment for the patients. 
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SUMMARY
 The canonical janus kinase (JAK)-signal transducer and activator of 
transcription (STAT) signaling pathway is a relatively simple but crucial membrane-
to-nucleus pathway that orchestrates the human immune system. Variants in human 
STATs result in severe immune dysregulation including autoimmune disease and 
immunodeficiency. Treatment of patients with STAT variants is mostly symptomatic 
and there remains a need for additional effective therapies (Chapter 1). Long-term 
use of antimicrobial therapies may lead to drug resistance and the effectiveness 
of several immune suppressive treatment modalities remains indefinite. Allogenic 
hematopoietic stem cell transplantation (HSCT) is the only curative treatment 
for patients with STAT variants, but has significant risk of secondary graft failure, 
infections and death. In this thesis, novel variants in STAT1 and STAT3 are presented. 
The studies were conducted to gain more insights in the biological and pathological 
effects of the described variants in STAT1 and STAT3, which could provide a basis 
for precise pathway-targeted therapeutic strategies.
 STAT1 gain-of-function (GOF) variants are identified as the underlying 
cause in about half of chronic mucocutaneous candidiasis (CMC) cases. Almost 
hundred heterozygous STAT1 GOF variants have been described in the past decade. 
STAT1 variants can be located in every domain of STAT1 but are mainly found in 
the coiled-coil domain and DNA binding domain. In Chapter 2 of this thesis, a 
novel STAT1 variant p.(V653I) is described in a Dutch family with four affected 
individuals. These patients suffer from CMC and various autoimmune phenomena. 
The identified variant is located in the SH2 domain of STAT1 and results in 
enhancement of STAT1 phosphorylation. In contrast to STAT1 variants located 
in other domains, an impaired STAT1 dephosphorylation rate was not observed. 
Expression levels of STAT1 regulated genes, CXCL9, CXCL10, and CD274 (PDL1) in 
patient-derived long-term T lymphocyte cultures were higher than those in healthy 
controls. Cytokine-induced PD-L1 expression in T lymphocytes was previously 
found to diminish Th17 development. The V653I variant is also associated with 
impairment of patient PBMCs to produce IL-17A, IL-17F, and IL-22 which are 
crucial cytokines for human antifungal immunity. A diminished Th17 response 
is considered to be responsible for the clinical symptoms of CMC in the patients 
described in this study. 
 The immunological findings in the first study provided a basis for pathway 
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targeted therapy in these patients (chapter 2.2). Based on the mechanism of action, 
a novel JAK1/2 inhibitor, baricitinib was proposed as a potential candidate. Prior to 
the treatment with baricitinib, the enrolled patient repetitively suffered from oral 
and esophageal candidiasis. Without systemic prophylactic antifungal therapy, she 
encountered candidiasis within two weeks. Our patients also experienced severe 
oral and vaginal ulcers which were assumed to represent autoimmunity related to 
the disease. After the treatment with baricitinib, the patient showed substantial 
clinical improvement. Prophylactic antifungal treatment and immunosuppressive 
therapy could be stopped without reappearance of candidiasis or ulcers. Baricitinib 
also decreased STAT1 hyperphosphorylation and increased IL-17A, IL-17F, and 
IL-22 production by the patient PBMCs. During treatment, expression levels of 
STAT1 targeted genes CXCL9 and CXCL10 were reduced, reaching levels comparable 
to those found in healthy controls. In this study we demonstrated, for the first time, 
the therapeutic efficacy of baricitinib in a patient with STAT1 GOF variant on both 
immunodeficiency and autoimmunity.
 We also demonstrated the benefit of baricitinib in a patient with Aicardi-
Goutières syndrome (AGS) based on a SAMHD1 variant in Chapter 4. The most 
prominent clinical feature was severe chilblains on hands and feet, which had been 
active over many years. Inflammation and pain were typically exacerbated after 
cold exposure. Within 6 weeks after initiation of baricitinib, the lesions completely 
resolved without reoccurrence for more than 2 years. The lesions also did not 
reoccur during winter. Five Interferon-stimulated genes (ISGs; IFI44, IFI44L, IFIT3, 
LY6E, and MX1) representing the gene signature for the activity of type I IFN were 
measured as disease markers. The elevated levels of ISGs, detected before initiation 
of baricitinib, remarkably declined during treatment. The hyperphosphorylation 
of STAT1 measured in T lymphocytes before baricitinib treatment also remarkably 
declined. Our findings suggest that baricitinib is a promising candidate for the 
treatment of chilblains in AGS patients with an upregulation of type I IFN activity.
 Novel STAT3 GOF variants are described in Chapter 3 of this thesis. We 
discovered two new STAT3 activating variants (p.[Y360C]) and p.[L387R]) in two 
families. From each family, two affected individuals were studied. Clinical signs 
and symptoms of these patients included immunodeficiency, autoimmune manifes-
tations, dysmorphic features, and chronic lung disease. All of the patients had 
elevated circulating levels of STAT3 regulated cytokines, IL-6 and IL-17. In vitro 
studies using HEK293 cells transduced with heterozygous STAT3 variants revealed 
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a defective nuclear translocation of the WT STAT3 allele, suggesting that these 
activating variants have a negative effect on the nuclear migration of the WT 
STAT3. These variants are also associated with increased STAT3 activity illustrated 
by luciferase reporter assays and the STAT3 downstream targeted gene, SOCS3, 
which is in line with the increased capacity to bind to target DNA. Non-canonical 
function of STAT3 in mitochondria was increased in the PBMCs carrying STAT3 
GOF variants. The oxygen consumption rate of patient PBMCs was significantly 
higher as compared to healthy controls. These variants are also associated with a 
reduction of naive T lymphocyte population and early exhaustion of T lymphocytes.
Two patients with the Y360C STAT3 GOF variant and late-stage disease were 
treated with tofacitinib. In one patient, who suffered from advanced stage refractory 
pulmonary hypertension, no effect of tofacitinib was observed. In the other patient 
with the Y360C STAT3 GOF variant, clinical condition improved upon treatment 
with tofacitinib. Pulmonary hypertension was well controlled, and no progression 
of disease was reported. 
In Chapter 5.1 and 5.2, we discuss the biological effects of each member of the STAT 
family and their clinical consequences. The similarity between the various STAT 
structures, competition with the same target genes, and heterodimer formation are 
all suggested as mechanisms for the shared clinical phenotypes found among STAT 
loss-of-function (LOF) and GOF variants.
In Chapter 5.3, treatment approaches targeting the JAK/STAT signaling pathway 
are discussed. We describe the treatment strategies used in our studies and the 
clinical outcomes. We further discuss the challenging future of new approaches for 
a more precise inhibition of JAK/STAT pathways in complex immune dysregulation 
disorders.
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SAMENVATTING
 De kenmerkende “Janus Kinase” (JAK) - “Signaltransducer and Activator 
of transcription” (STAT) signaalroute is een relatief eenvoudige maar cruciale 
celmembraan-tot-celkern moleculaire verbindingsweg die een belangrijke 
functie heeft in het menselijke immuunsysteem. In het menselijk lichaam zijn 
7 STAT moleculen geïdentificeerd. Mutaties in de menselijke STAT moleculen 
resulteren in een ernstige ontregeling van het immuunsysteem, deze leiden tot 
immuundeficiëntieziekten (afweerstoornissen) of auto-immuunziekten en soms 
een combinatie van beiden. Effectieve rationele therapieën voor patiënten met 
STAT-mutaties zijn momenteel nog niet uitontwikkeld (hoofdstuk 1). Gebruik van 
antimicrobiële medicijnen kunnen op termijn leiden tot resistentie van micro-or-
ganismen tegen deze geneesmiddelen en in het geval van auto-immuniteit is de 
effectiviteit van de verschillende immuun-onderdrukkende therapieën beperkt. 
Hematopoietische stamceltransplantatie (HSCT) ofwel beenmergtransplantatie en 
gentherapie zijn momenteel de enige curatieve therapieën maar hebben een ernstig 
bijwerkingenpatroon en zijn bovendien beperkt beschikbaar. 
 In dit proefschrift worden nieuwe mutaties in STAT1 en STAT3 
gepresenteerd. De beschreven studies werden verricht om meer inzicht te verkrijgen 
in de biologische en pathologische effecten van de mutaties en om in geval van 
ziekte aangrijpingspunten te identificeren voor een op de individuele patiënt 
gerichte therapie.
 STAT1 gain-of-function (GOF) mutaties die een verhoogde STAT1 
functie veroorzaken zijn voor ongeveer de helft verantwoordelijk voor chronische 
mucocutane candidiasis (CMC) bij patiënten. Bijna honderd heterozygote STAT1 
GOF-mutaties zijn het afgelopen decennium gepubliceerd. De mutaties bevinden 
zich in elk domein van het STAT1 molecuul, maar worden voornamelijk gevonden 
in het regulatie domein en het DNA-bindend domein. In hoofdstuk 2 van dit 
proefschrift wordt een nieuwe STAT1-mutatie p.(V653I) beschreven in een 
Nederlands gezin met vier aangedane individuen. Deze patiënten leden aan de 
combinatie van CMC en verschillende auto-immuunziekten. De gevonden mutatie 
bevindt zich in het SH2-domein van STAT1 en resulteert in STAT1-hyperfosfor-
ylering. Hyperfosforylering is een proces wat nodig is om STAT1 te activeren. In 
tegenstelling tot de mutaties die zich in andere domeinen bevinden, werd een 
verminderde STAT1-defosforylatie niet waargenomen. Expressie van de door 
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STAT1 gereguleerde genen, CXCL9, CXCL10 en CD274 (PDL1) in lange termijn 
T-lymfocytenkweken van de patiënt waren hoger dan die van de gezonde controles. 
Cytokine-geïnduceerde PD-L1-expressie door de T-lymfocyten bleek de belangrijke 
Th17-productie te verminderen. De V653I-mutatie wordt dan ook direct geasso-
cieerd met een verminderde IL-17A, IL-17F en IL-22T productie door T-lymfocyten, 
dit zijn de cruciale cytokines die nodig zijn voor de afweer tegen schimmels. De 
verminderde Th17-respons in deze studie wordt dan ook beschouwd als een 
verklaring voor de klinische symptomen van CMC bij deze patiënten.
 De immunologische bevindingen in de voorgaande studies gaven directe 
aanwijzingen om een gerichte therapie te starten bij deze patiënten (hoofdstuk 2.2). 
Op basis van het werkingsmechanisme, werd de nieuwe JAK1/2-remmer baricitinib 
voorgesteld als een potentiële kandidaat voor de behandeling van deze patiënten 
met een STAT-1 GOF-mutatie. Vóór de start met baricitinib leed de beschreven 
patiënt continue aan orale en slokdarm schimmelinfecties (candidiasis). Chronische 
behandeling met profylactische antischimmelmedicatie was noodzakelijk want 
anders ontwikkelde de patiënt in twee weken tijd wederom candidiasis. De patiënt 
ontwikkelde verder ook orale en vaginale ulceraties waarvan werd aangenomen 
dat ze ontstonden op basis van auto-immuniteit. De behandeling met baricitinib 
resulteerde in een sterke klinische verbetering. Profylactische antischimmelbehan-
deling en immunosuppressieve therapie konden worden gestopt zonder nieuwe 
verschijnselen van candidiasis of ulceraties. Baricitinib verlaagde ook de hyperfosfo-
rylering van STAT1 en verhoogde de productie van IL-17A, IL-17F en IL-22 door de 
witte bloedcellen van de patiënt. Gedurende de behandeling was de expressie van de 
door STAT1 gereguleerde genen CXCL9 en CXCL10 verminderd en benaderde het 
niveau van gezonde controles. Op basis van deze bevindingen hebben we voor de 
eerste keer de therapeutische effectiviteit van baricitinib aangetoond bij een patiënt 
met STAT1 GOF-mutatie.
 We hebben verder ook het positieve effect aangetoond van baricitinib bij 
een patiënt met het Aicardi-Goutières-syndroom (AGS), dit zijn patiënten met 
een SAMHD1-mutatie, zoals beschreven in hoofdstuk 4. De beschreven patiënt 
had ernstige klinische symptomen zoals doorbloedingsstoornissen aan handen 
en voeten. De ontstekingen en pijn verergerden sterk na blootstelling aan koude. 
Binnen 6 weken na de start van baricitinib was het probleem van de “winterhanden/
voeten” opgelost en dit persisteerde 2 jaar lang. De laesies kwamen dan ook niet 
terug in de winter. Vijf van de door interferon type I geactiveerde genen (ISG’s; 
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IFI44, IFI44L, IFIT3, LY6E en MX1) die de “handtekening” vertegenwoordigen van 
(verhoogde) type I IFN activiteit, werden gemeten als marker voor ziekteactiviteit. 
De verhoogde ISG’s niveaus zoals gemeten vóór de start van baricitinib, daalden 
aanzienlijk tijdens de behandeling. De hyperfosforylering van STAT1 welke werd 
gemeten in de T-lymfocyten vóór de behandeling met baricitinib was ook duidelijk 
afgenomen. Onze bevindingen suggereren dat baricitinib een veelbelovende nieuwe 
kandidaat is voor de behandeling van AGS-patiënten. 
 Nieuwe STAT3 GOF-mutaties worden beschreven in hoofdstuk 3 van dit 
proefschrift. We beschrijven twee nieuwe STAT3 activerende mutaties (p.[Y360C]) 
en p.[L387R]) in twee families. Van elke familie waren twee patiënten onder 
behandeling. De klinische symptomen van de patiënten omvatten immuundefi-
ciëntie, auto-immuunverschijnselen, groei en dysmorfe kenmerken en chronische 
longziekte. Alle patiënten hadden verhoogde, door STAT3-gereguleerde cytokines 
IL-6 en IL-17. In vitro studies met getransduceerd HEK293-cellen met de hetero-
zygote STAT3-mutaties lieten een defect transport van het wild-type (WT) 
STAT3 naar de kern zien, wat suggereert dat de activerende mutaties een negatief 
effect hebben op transport van WT STAT3. De STAT3 mutaties veroorzaken 
een verhoogde transcriptie van STAT3 afhankelijke genen zoals aangetoond met 
luciferase reporter-assays, en ook toename van STAT3 “downstream” geregu-
leerde genen zoals SOCS3. Een tot nu toe niet bestudeerde functie van STAT3 in 
afweerstoornissen is het niet-klassieke effect van STAT3 op mitochondriën. Dit 
werd verricht op mononucleaire witte bloedcellen en toonde een verhoogde functie 
van de mitochondriën in het geval van de twee GOF-mutaties. Deze mutaties zijn 
ook geassocieerd met vermindering van naïeve T-lymfocytenpopulatie en vroege 
uitputting van T-lymfocyten. Verschuiving van de lymfocytenpopulaties zou ook 
een bijdrage kunnen leveren aan de veranderde mitochondriale functies omdat 
de verschillende subtypen lymfocyten een potentiele verandering in metabolisme 
ondergaan tijdens differentiatie. 
 Er werd een behandeling gestart met tofacitinib, ook een JAK-remmer, 
van de twee patiënten met de Y360C STAT3 GOF-mutatie die in een gevorderd 
stadium van ziekte verkeerden. Bij een van de patiënten met refractaire pulmonale 
hypertensie werd vrijwel geen effect van tofacitinib waargenomen. Bij de andere 
patiënt met Y360C STAT3 GOF-mutatie verbeterden haar klinische verschijnselen 
gedurende de behandeling. De pulmonale hypertensie bleef onder controle tijdens 
de behandeling met tofacitinib want deze recidiveerde niet. Bovendien verdween de 
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cachexie tijdens de behandeling.
 In hoofdstuk 5.1-5.2 wordt de functie van het STAT-eiwit in termen van 
biologie en klinische consequenties bediscussieerd. De gelijkenis van alle STAT-mol-
eculen, competitie voor dezelfde doelwitgenen en heterodimeervorming worden 
gepostuleerd als de mechanismen die verantwoordelijk zijn voor de overeenkomstige 
klinische fenotypes die worden gevonden bij zowel STAT-functieverlies (LOF) en bij 
GOF-mutaties.
 In hoofdstuk 5.3 worden de behandelingsmogelijkheden beschreven die 
zijn gericht op de interactie met de JAK/STAT-signaalroute, zoals ook in onze studies 
toegepast. We bespreken verder nieuwe ontwikkelingen die moeten uitmonden in 
remming van de JAK/STAT-signaalroutes, om zodoende te komen tot effectievere 
therapieën met een acceptabel bijwerkingenpatroon. 
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matter how late we had to stay for the experiments, you never gave up. We got a 
number of Kaiser points, although we do not really know how to claim these points 
and what are they for. I really appreciate everything you have done for me. You also 
my model for zero-waste lifestyle and to eat less meat (being vegetarian is still too 
difficult for me). It was funny that I decided to have a pack of mango for breakfast 
instead of a bacon-cheese croissant after you introduced me to watch Okja. You are 
a truly great man with an extremely good heart. I was so lucky that I met you and 
once being your colleague.
 Dear Pamela, If I could say only one sentence to you, I would ask you that 
why did we just met in my last year of PhD? Working with you was a pleasure. You 
helped me a lot, both in the lab and outside. I truly appreciate your helps which 
made me pass through the challenging time of my PhD. Having you around me 
made everything I had to do more delightful. Working in the lab had never been so 
fun. I remember when we chitchatted about stuff til we went back home late. You 
also helped me preparing my room for the moving out and that really cheered me 
up much more than when I had to do it alone. You were the only one in the lab who 
ever asked me if I had something to eat for my dinner and offered to bring me food 
(and gumdrops >v<). I would like to thank you for being both my colleague and my 
friend. Although we were around together for only about half a year, it was really a 
good time. I’m glad that I met you. Maybe I am not your lazy boss (haha) anymore, 
but you are my friend, forever.     
 Conny! How can we work without you? You know the best where all the 
stuff in the lab are and always manage to arrange everything nice and tidy! Thank 
you so much for every help and advice. ELISA queen did give part of her power to 
me. Nicole, I truly appreciate your help especially with the flow cytometry. You 
taught me how to work with it and I did need to do flow in every of my project. 
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Maaike, I’m so thankful for your help in RQ-PCR and also other stuff. You did work 
hard for me, and everything turned out brilliant! IRD group colleagues, I’m glad 
that once I was part of this team. I’m so thankful for all of your help and kindness. 
I will miss working in the lab with all of you. 
 Fabian, Super Chang! You helped me with a lot of things in the lab. I really 
appreciate everything you had done for me. Your advice always made me learn 
something new. You are the most hard-working student I have ever met, and you 
are handy with almost every tool and process in the lab. I believe that one day you 
will be a great scientist as well as a great doctor. Your success is approaching, just 
keep going and be patient. Please do not forget that Chang never give up! 
 Christopher, your calm and kindness make you the most amazing person. 
Ever since I have known you, you made me smile or laugh every time we met, even 
within a few minutes at the hallway. You know plenty of techniques in the lab and 
you willing to help out wherever there is a need. I thought that if there are so many 
people bother me the way I and other people did to you, I probably feel annoyed. 
On the contrary, you never looked irritated at all. Your office door never closed. Your 
thoughtful and kindness are my model and I want to be a great scientist like you.    
 Dear my officemates Marieke, Iris, Jamie, and Steven, it was nice to meet 
you guys. Marieke, we shared the same office since I started working in EMC. I am 
sorry that I missed your promotion day. I am sure you are doing great with your 
new job. Iris, you started your PhD almost at the same time with me. I remembered 
you taught me to do PBMC isolation and I still used your protocol until now. At 
the beginning, I did not speak a lot to anybody. You were almost the only one in 
the lab I talked to. Since we get familiar with each other, we did chitchat a lot in 
the office :) Jamie and Steven, I hope you are doing well. Your diligence and your 
patient will bring you success. You were always nice to me and we helped each other 
whatever we can do in our office. Iris, Jamie, and Steven, I will not forget our great 
times at Takumi and Shabu Shabu. I hope when I have an opportunity to go back to 
Rotterdam again, we will have time to dine out together somewhere. 
 Chris and Jenna, you are among the persons I must say that I was so lucky 
to meet you. I had a hard time at the beginning of my PhD, and you did help me 
with all your advice and your friendliness. Jenna, you were nice to everyone and it 
was sad to see you leave EMC while Chris and I still had to work in the lab. I very 
much appreciate your help on flow cytometry and also other stuff. Chris, you were 
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always nice to me. It was fun that we shared matcha treats with each other. I hope 
you have a plan to visit Bangkok again. There are plenty of tea bars and dessert cafes 
pop up that I want to go with you.
 Hanna Kok, although you left EMC not so long after we met, we had a very 
good time together. You taught me to do transfection and it did work very well. 
We went to cinema together which was my first time in Rotterdam. I hope you 
are doing great at your current work place. I am still stalking you on Facebook and 
Instagram ;) 
 Astrid, we met only half a year before I left EMC. You are such a cheerful 
person with a thoughtful mind. Talking to you did cheer me up. It was a pity that 
we did not go to the museum together but at least we spent good time at our 
workplace. I am glad that I could help you out with some tiny little things in the lab 
which also made me feel good to myself. I think I cannot go to your graduation day 
:( sorry, but I am sure that you did brilliant jobs in your study.    
 Olivia, we had a fantastic time in Lisbon! Thank you for hanging around 
with me there. Everything was so nice. You still need to work with Virgil, sorry 
for that, haha (just kidding). I’m sure you will do very well in your PhD. Looking 
forward to seeing you around again soon in the congress somewhere.
 Jorn, the Lion! Having you around in the lab was so fun. Martijn, you are 
the politest Dutch guy I ever met (in contrast to Jorn, haha). Both of you are nice 
guy. Thank you so much for being around and helping me with all the stuff. You are 
very smart and I’m sure you will do great in your PhD. 
 Dear all my colleague in Department of Immunology ErasmusMC, I want 
to take this opportunity to thank all of you for your support and care you had given 
me while we worked together. It was a big adaptation for me to work there, at the 
beginning. I have to learn numerous of new things and I would never be able to 
do it without your (either direct or indirect) guidance and help. I tried to be nice 
to everyone as much as possible and I’m sorry if I did disappoint any of you for 
whatever reasons. Thank you for making this workplace such an amazing place that 
gave me plenty of experiences. I have already missed all of you. Working without 
anyone of you is never be the same. I promised that if I have an opportunity to go to 
the Netherlands or nearby, I will definitely visit you all again.
 Dear my friends and colleagues in Thailand, although our life, times, and all 
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the situations have changed over the years, but our wonderful bonding stays. Thank 
you so much for your support and trust in me. All the good time we spent together 
were one of the drives for me to finish my PhD as soon as possible and come back 
to see you again in Thailand. 
 Here, I would like to also express my special gratitude to my collaborators, 
Peter J. van der Spek, Sigrid MA Swagemakers, Chiara Milanese, Pier G. 
Mastroberardino, Angelique van Rijswijk, Sandra J. Posthumus-van Sluijs, Cornelia 
G. van Helden-Meeuwsen, Marjan A. Versnel, Emilia K. Bijlsma, Claudia A. L. 
Ruivenkamp, Margreet J. Oele, Deon J. Venter, Narissara Suratannon, and other 
collaborators for your valuable support and contribution in this thesis. 
 Last but not least, I would like to thank my family who always support me. 
We not usually say love to each other, but I want you to know here that you are the 
most crucial persons in my life. Mom and Papa, you worked hard together since I 
was very young to provide me excellent educations. Although I had to study until 
late several days per week and also on the weekends, you were always by my side. 
No matter what I want to study and try, you always support me, and we aim for the 
best. This make me learn to commit myself to excellence. Parenting a child to grow 
up to be a strong and successful adult is extremely difficult, but I think you did it 
very well. Without you, it is impossible for me to be here. You are truly the wind 
beneath my wings.
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PhD PORTFOLIO 
Summary of PhD training and teaching
Kornvalee Meesilpavikkai
Erasmus MC, Department of Internal Medicine, Department of 
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Research School: MolMed Erasmus University
PhD period: 2015-2019
ACTIVITIES YEAR WORKLOAD (ECTS)
Courses
Introduction in GraphPad Prism 2015 0.3
Annual Course on Molecular Medicine 2016 0.7
CC02a course Biostatistical Methods I: Basic 
Principles Part A (Nihes) 2016 2
XVth Course Biomedical Research Techniques 2017 1.5
Scientific integrity course 2017 0.3
Biomedical English Writing & 
Communication 2017 3
Ensembl Gene Browsing workshop 2018 0.6
Advance Immunology Course 2018 4.5
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ACTIVITIES YEAR WORKLOAD (ECTS)
Presentations and (inter)national 
conferences
Poster presentation in the International 
Primary Immunodeficiencies Congress 
(IPIC), Budapest, Hungary
2015 1
Presentation in international research 
meeting between Faculty of Medicine 
Chulalongkorn University and Erasmus 
University Medical Center International 
Symposium 2015: Nephrology, Dermatology, 
Endocrinology and Immunology, Bangkok, 
Thailand
2015 1
Poster presentation in Wetenschapsdagen 
2016, Antwerp, Belgium 2016 1
Poster presentation in 20th Molecular 
Medicine Day 2016, Rotterdam, the 
Netherlands
2016 1
Poster presentation in 17th biennial 
meeting of the European Society for 
Immunodeficiencies (ESID), Barcelona, Spain
2016 1
Oral presentation in 10th European Workshop 
on Immune-Mediated Inflammatory Diseases 
(EWIMID), Toulouse, France
2016 1
Poster presentation in Wetenschapsdagen 
2017, Antwerp, Belgium 2017 1
Poster presentation in 21th Molecular 
Medicine Day 2017, Rotterdam, the 
Netherlands
2017 1
Presentation in Dutch WID Immunology 
Expert Meeting on PID 2017, Santpoort, the 
Netherlands
2017 1
Presentation in Internal Medicine Research 
Symposium 2017 0.4
Poster presentation in the International 
Primary Immunodeficiencies Congress 
(IPIC), Dubai, Emirates
2017 1
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ACTIVITIES YEAR WORKLOAD (ECTS)
Attend the Second International Primary 
Immunodeficiency Meeting: From Bench to 
Bedside, Chulalongkorn University, Bangkok 
Thailand
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Poster presentation in Wetenschapsdagen 
2018, Antwerp, Belgium 2018 1
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Medicine Day 2018, Rotterdam, the 
Netherlands
2018 1
Poster presentation in 20th Congress of the 
International Society for Human and Animal 
Mycology, Amsterdam, the Netherlands
2018 1
Attend Diagnostics in Medical Mycology 
Workshop, Faculty of Medicine 
Chulalongkorn University, Bangkok, Thailand
2018 1
Poster presentation in 18th biennial 
meeting of the European Society for 
Immunodeficiencies (ESID), Lisbon, Portugal
2018 1
Poster presentation in the 7th Federation 
of Immunological Societies of Asia-Oceania 
Congress (FIMSA 2018), Bangkok, Thailand
2018 1
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hours) 2017 0.3
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Total ECTS 36.9
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